Hematology

ALL

Questions discussed in this category

Would you offer intensive CNS prophylaxis to Ph negative B-ALL patients who have possible mandibular nerve involvement on MRI face?

The patient presented with a numb chin, more to the right of his face; an MRI did report mandibular nerve opacity, which is non-specific per neuro-rad...

1 Answer available

How do you address logistic barriers related to blinatumomab when treating relapsed B-ALL?

For example, if patients are unable to receive continuous infusion from home health agencies, or if prolonged hospitalization is cost-prohibitive.&nbs...

2 Answers available

How do you manage severe hypertriglyceridemia in the adolescent & young adult population receiving chemotherapy for ALL, in the absence of complications related to hypertriglyceridemia?

1 Answer available

Does the presence of asparaginase antibodies on Granger Genetics testing indicate need to switch asparaginase formulations?

1 Answer available

In what situations do you use G-CSF for patients undergoing allogeneic HSCT to facilitate engraftment?

How does graft source, conditioning regimen, and indication for transplant affect your decision regarding G-CSF?

2 Answers available

What is your practice regarding giving G-CSF to patients with ALL during initial induction?

The patient was recently diagnosed with pre-B ALL and is on day 10 of CALGB 10403. He is expectedly neutropenic as he received daunorubicin and vincri...

2 Answers available

Would you consider post-BMT maintenance therapy for patients with Ph-like ALL with a JAK2 mutation?

1 Answer available

Do you check asparaginase levels for all patients receiving receiving E. coli-derived products, or only in certain clinical situations?

1 Answer available

How do you mitigate 6-MP-induced GI toxicity in pediatric and AYA patients with leukemia?

2 Answers available

What is the treatment of choice for mixed phenotype ALL?

What are the differences in approach to B lymphoid/myeloid and T lymphoid/myeloid MPAL?

1 Answer available

Is there a role for IL2-receptor antagonists and TNF-alpha inhibitors in cytokine release syndrome as a complication of CAR-T or immunotherapy?

1 Answer available

What criteria is needed in relapsed/refractory B-cell ALL to choose CAR-T therapy over conventional stem cell transplant as destination therapy?

1 Answer available

What is your approach to pediatric or AYA patients with B-cell ALL who relapse after CD-19 CAR-T?

1 Answer available

How do you approach IVIG replacement for pediatric patients with low IgG during treatment for hematologic malignancies?

Do you routinely check IgG levels during therapy, if not indicated by a study protocol?

1 Answer available

How do you decide between blinatumomab or traditional chemotherapy in combination with TKI for upfront treatment of adult patients with Ph + ALL?

1 Answer available

What maintenance treatment would you recommend for Ph positive ALL following Hyper-CVAD, transplant eligible or ineligible?

1 Answer available

For pre-menopausal female patients who present with acute leukemia in need of urgent anti-neoplastic therapy, what is your preferred approach in effort to preserve fertility?

Does acute leukemia sub-type affect your decision?

1 Answer available

When during ALL induction therapy are you checking for MRD?

1 Answer available

Do you prefer hyper-CVAD or the CALGB 9111 protocol for high intensity remission induction treatment in Ph-negative ALL patients?

The NCCN recommends both regimens.

1 Answer available

Papers discussed in this category

Fertil. Steril., 2013 Sep 05

Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion.

Cancer, 2014-12-01

Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).

Blood, 1998-09-01

A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111.

Blood, 2019-04-04

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.

American journal of hematology, 2018-08

Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD.

Am. J. Hematol., 2019 Nov 19

The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival.

Blood, 2016-07-28

Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Blood advances, 2016-12-27

US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL.

Cancer, 2016-10

Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Blood, 2017-08-31

Posttransplant feasibility study of nilotinib prophylaxis for high-risk Philadelphia chromosome positive leukemia.

Biol. Blood Marrow Transplant., 2019 Aug 22

Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy.

Blood,

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Blood, 2018 Apr 5

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.

N Engl J Med,

Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009-10

Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Journal of pediatric hematology/oncology, 2019-08

Impact of IgG Monitoring and IVIG Supplementation on the Frequency of Febrile Illnesses in Pediatric Acute Lymphoblastic Leukemia Patients Undergoing Maintenance Chemotherapy.

J Clin Oncol, 2021 Dec 9

Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.

Blood Cancer Discov, 2021 Dec 01

Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia.

Exp Hematol Oncol, 2021 Feb 19

Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy.

Front Oncol, 2020 Jul 16

Use of Allopurinol to Mitigate 6-Mercaptopurine Associated Gastrointestinal Toxicity in Acute Lymphoblastic Leukemia.

Leukemia, 2021 Jun 26

DNA-thioguanine concentration and relapse risk in children and young adults with acute lymphoblastic leukemia: an IPD meta-analysis.

Haematologica, 2021 Nov 01

Increments in DNA-thioguanine level during thiopurine-enhanced maintenance therapy of acute lymphoblastic leukemia.

JAMA, 2021 Mar 02

Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.

American journal of hematology, 2024 Feb 05

Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia.

JCO precision oncology, 2023 May

Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in Class Rearrangements.

Pediatric blood & cancer, 2015-06

Clinical application of asparaginase activity levels following treatment with pegaspargase.

Leukemia & lymphoma, 2018-08

Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia.

Haematologica, 2016 Mar

Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation.

Archives of drug information, 2008-12

A Phase 3, Randomized, Placebo-controlled Trial of Filgrastim in Patients with Haematological Malignancies Undergoing Matched-related Allogeneic Bone Marrow Transplantation.

Bone marrow transplantation, 2003 Jul

G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003 Dec 22

Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Leukemia, 2005 Apr

Graft-versus-host-disease and granulocyte colony-stimulating factor administration after allogeneic stem cell transplantation.

Transplantation and cellular therapy, 2021 Oct 02

Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy.

Medicina oral, patologia oral y cirugia bucal, 2008 Oct 01

Malignant mental nerve neuropathy: systematic review.

Blood, 2023 Mar 23

How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia.

Related Topics in Hematology